|
Bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs) are two inspiring methods to the treatment of cancers in various clinical studies. In the development of therapeutic ADCs, strategies for optimizing ADCs about antibodies mainly include enhancing specificity, affinity, and internalization. The rapid development of BsAb technology contributes to more choices of antibodies as a partner of ADCs.
Conjugating payload into BsAb to improve specificity and internalization, called bispecific ADCs (BsADCs), which may be a solution to the existing problems of endocytosis, toxicity, and drug resistance of ADCs. besides, BsADCs are also a viable route to increase tumor selectivity while retaining highly potent antitumor efficacy.
| 
